Purchase this article with an account.
Donald C. Hood, Emmanouil Tsamis, Nikhil K. Bommakanti, Devon B. Joiner, Lama A. Al-Aswad, Dana M. Blumberg, George A. Cioffi, Jeffrey M. Liebmann, Carlos G. De Moraes; Structure-Function Agreement Is Better Than Commonly Thought in Eyes With Early Glaucoma. Invest. Ophthalmol. Vis. Sci. 2019;60(13):4241-4248. https://doi.org/10.1167/iovs.19-27920.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the agreement between structural (optical coherence tomography [OCT]) and functional (visual field [VF]) glaucomatous damage with an automated method and deviation/probability maps, and to compare this method to a metric method.
Wide-field spectral-domain OCT scans, including the disc and macula, and 24-2 and 10-2 VFs were obtained from 45 healthy control (H) eyes/individuals, and 53 eyes/patients with 24-2 mean deviation (MD) better than −6 dB diagnosed as “definite glaucoma” (DG) by experts. Abnormal structure–abnormal function (aS-aF) agreement was assessed with an automated topographic (T) method based upon VF pattern deviation and OCT probability maps. Results were compared to a metric (M) method optimized for accuracy, (abnormal 24-2 glaucoma hemifield test [GHT] or pattern standard deviation [PSD], or 10-2 PSD AND abnormal OCT [quadrant]).
For the T-method, 47 (88.7%) of the 53 DG eyes showed aS-aF agreement, compared to 2 (4.5%) of the 45 H eyes. The aS-aF agreement for these two H eyes was easily identified as mistaken, and did not replicate on a subsequent test. Without the 10-2, the aS-aF agreement decreased from 47 to 34 (64.2%) of 53 DG eyes. For the M-method, 37 (69.8%) of the 53 DG eyes showed aS-aF agreement, while omitting the 10-2 VF resulted in agreement in only 33 (62.3%) eyes.
There is good agreement between structural and functional damage, even in eyes with confirmed early glaucomatous damage, if both 24-2 and 10-2 VFs are obtained, and abnormal locations on the VFs are compared to abnormal regions seen on OCT macular and disc scans. This can be done in an objective, automated fashion. (ClinicalTrials.gov number, NCT02547740.)
This PDF is available to Subscribers Only